Marinus Pharmaceuticals (NASDAQ:MRNS) Rating Lowered to Sell at StockNews.com

Marinus Pharmaceuticals (NASDAQ:MRNS - Get Free Report) was downgraded by equities research analysts at StockNews.com from a "hold" rating to a "sell" rating in a research note issued on Thursday.

Several other brokerages also recently issued reports on MRNS. Truist Financial reiterated a "buy" rating and issued a $10.00 price target on shares of Marinus Pharmaceuticals in a report on Tuesday, June 18th. HC Wainwright reiterated a "buy" rating and issued a $11.00 price target on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. Finally, LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a "buy" rating to a "neutral" rating in a report on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, Marinus Pharmaceuticals presently has an average rating of "Hold" and a consensus target price of $12.75.

Marinus Pharmaceuticals Trading Down 3.6 %

Shares of MRNS stock traded down $0.05 on Thursday, reaching $1.32. 213,498 shares of the stock were exchanged, compared to its average volume of 1,206,075. The stock has a market cap of $72.51 million, a P/E ratio of -0.50 and a beta of 1.13. The company has a quick ratio of 2.93, a current ratio of 3.07 and a debt-to-equity ratio of 5.68. The firm has a 50 day moving average of $1.32 and a two-hundred day moving average of $4.12. Marinus Pharmaceuticals has a 1-year low of $1.05 and a 1-year high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS - Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.01). The firm had revenue of $8.06 million for the quarter, compared to analyst estimates of $9.05 million. Marinus Pharmaceuticals had a negative return on equity of 518.13% and a negative net margin of 513.80%. During the same quarter in the previous year, the company earned ($0.61) earnings per share. On average, research analysts anticipate that Marinus Pharmaceuticals will post -1.87 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC increased its holdings in shares of Marinus Pharmaceuticals by 70.3% in the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company's stock valued at $37,000 after purchasing an additional 12,934 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Marinus Pharmaceuticals during the second quarter worth $64,000. Squarepoint Ops LLC bought a new stake in Marinus Pharmaceuticals in the 2nd quarter valued at $206,000. Point72 DIFC Ltd bought a new stake in Marinus Pharmaceuticals in the 2nd quarter valued at $28,000. Finally, XTX Topco Ltd bought a new stake in Marinus Pharmaceuticals in the 2nd quarter valued at $232,000. Institutional investors own 98.80% of the company's stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.